WASHINGTON — Vaping companies have just nine days until they must submit formal marketing applications to the Food and Drug Administration, or risk being kicked off the market. Now, small vapor companies are requesting an extension, setting off a flurry of activism in recent days from both vaping advocates and tobacco control groups.

Vaping companies must submit so-called premarket tobacco product applications by Sept. 9. These sweeping applications must include a slew of information, including scientific data on the manufacturing processes and chemical components of a product, as well as answers to questions like how likely a product is to be misused by children, and whether a product helps cigarette smokers quit. It’s the most make-or-break moment in the industry’s short, chaotic history: Companies that don’t submit applications will likely be put out of business, as will companies that see their applications rejected by the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy